آزمون آزمایشی OET Reading شماره 2

Text A: Epidemiology of Hepatitis B

Hepatitis B virus (HBV) infection remains a significant global health challenge, affecting approximately 254 million people worldwide, according to the World Health Organization (WHO). The virus is transmitted through blood, sexual contact, or perinatal exposure from mother to child. High-prevalence regions include sub-Saharan Africa and East Asia, where up to 10% of the population may be chronically infected. In contrast, low-prevalence areas like North America and Western Europe report rates below 1%. High-risk groups include healthcare workers, individuals with multiple sexual partners, and people who inject drugs. While vaccination programs have reduced incidence in some regions, barriers such as limited healthcare access and low awareness hinder progress. The WHO aims to eliminate HBV as a public health threat by 2030, targeting a 90% reduction in new infections. (134 words)

Text B: Clinical Spectrum

HBV infection manifests as either acute or chronic disease. Acute hepatitis B is often asymptomatic but may present with fever, jaundice, and fatigue, resolving within six months in 90% of adults. However, 5–10% of cases, particularly in infants infected perinatally, progress to chronic hepatitis B (CHB). CHB can lead to severe complications, including cirrhosis (liver scarring) and hepatocellular carcinoma (HCC), a primary liver cancer. Approximately 20–30% of CHB patients develop cirrhosis over decades, and 2–5% of those with cirrhosis progress to HCC annually. Disease progression is influenced by host factors, such as immune response, and viral factors, like HBV genotype. Regular monitoring is essential to detect complications early and initiate timely interventions. (112 words)

Text C: Diagnostic and Screening Methods

Screening for HBV is recommended for high-risk groups, including pregnant women and healthcare workers. Diagnostic methods include serological tests detecting hepatitis B surface antigen (HBsAg), which indicates active infection, and hepatitis B e antigen (HBeAg), suggesting high viral replication. Polymerase chain reaction (PCR) assays quantify HBV DNA to assess viral load. Liver fibrosis is staged using liver biopsy or non-invasive tools like transient elastography (FibroScan). The American Association for the Study of Liver Diseases (AASLD) guidelines advocate screening in endemic areas and monitoring viral load and liver function tests (ALT) every 6–12 months for CHB patients. Accurate diagnosis is critical to guide treatment and prevent progression to advanced liver disease. (116 words)

Text D: Treatment Strategies

Antiviral therapy is the cornerstone of chronic hepatitis B (CHB) management. Nucleos(t)ide analogues, such as entecavir and tenofovir, suppress viral replication, reducing liver damage. These drugs achieve undetectable HBV DNA in over 95% of patients after one year. Treatment decisions are guided by viral load, ALT levels, and liver fibrosis stage. WHO and AASLD guidelines recommend lifelong therapy for most CHB patients to prevent relapse. Emerging therapies, including RNA interference and immune modulators, aim for a functional cure (loss of HBsAg). Clinical trials are exploring combination therapies to enhance cure rates. Patient adherence and regular monitoring are vital to ensure treatment success and prevent drug resistance. (117 words)

Text 1: Memo on Patient Communication

Subject: Enhancing Empathy in Cancer Care

To: All Oncology Staff

From: Dr. Sarah Lee, Head of Oncology

Date: June 10, 2025

Patient feedback, including from Georgina Johnson, a 48-year-old with stage 3 bowel cancer, emphasizes the need for empathetic communication during cancer diagnoses. Overloading patients with technical details initially can increase anxiety and erode trust. Staff should focus on essential information, such as diagnosis and immediate next steps, while assessing patients' readiness for further details through active listening and open-ended questions. Reassure patients about symptom management and support services, like counseling or peer groups. This approach strengthens trust, improves treatment adherence, and enhances outcomes. Mandatory training on empathetic communication, including role-playing and case studies, is scheduled for June 15–17. Register by June 12 via the HR portal. Non-attendance may affect performance reviews. Contact HR (ext. 320) for scheduling conflicts or additional resources. (171 words)

Text 2: Hospital Policy Update

Subject: Immigration Enforcement in Healthcare Settings

To: All Staff

From: Legal Department

Date: May 1, 2025

As of January 2025, the U.S. "sensitive locations policy" no longer protects healthcare facilities from immigration enforcement. U.S. Immigration and Customs Enforcement (ICE) officials may access public areas (e.g., lobbies, cafeterias) without a warrant but require a judicial warrant for private areas (e.g., exam rooms, wards). Staff must not share protected health information (PHI), including immigration status, without a verified warrant. Contact the Legal Department (ext. 450) to authenticate warrants and log all ICE interactions in the hospital's incident report system. Designate private areas with clear signage by May 15 to protect patient privacy. Mandatory training on compliance protocols is scheduled for May 10, with refresher sessions quarterly. Non-compliance risks legal penalties and patient safety. Contact the Legal Department for policy documents or support. (180 words)

Text 3: Research Brief to Midwives

Subject: Trimethoprim–Sulfamethoxazole Trial Results in Pregnancy

To: Maternity Ward Staff

From: Research Committee

Date: June 5, 2025

The COMBI trial in Zimbabwe tested trimethoprim–sulfamethoxazole (TMP-SMX) prophylaxis in pregnancy to improve birth outcomes in high HIV-prevalence areas. Involving 993 women, the study administered TMP-SMX (960 mg daily) or placebo from ≥14 weeks' gestation until delivery. No significant birth weight improvement was observed (3040 g vs. 3019 g, placebo; P=0.53). However, preterm births were significantly reduced (6.9% vs. 11.5%; relative risk, 0.60; P=0.013). Adverse events were similar across groups. Safety data supports TMP-SMX's safety in pregnancy. Routine use is not yet recommended, pending WHO guidelines expected in 2026. Staff should discuss these findings with patients and emphasize early prenatal care. Access the full study via the Research Committee's portal or contact us for a briefing. (175 words)

Text 4: Clinical Guideline Update

Subject: Revised Anemia Diagnosis Standards

To: General Practitioners

From: Medical Board

Date: June 6, 2025

Following research and ethical debates, anemia diagnosis guidelines have been revised to eliminate race-based biases. Previously, hemoglobin cutoffs for Black patients were lower (0.5–1.0 g/dL) due to observed averages. Evidence now links these differences to environmental factors, like nutrition or socioeconomic disparities, or hemoglobinopathies, not biologic race. The CDC and American College of Obstetrics and Gynecology (ACOG) mandate uniform thresholds: 11.0 g/dL for children and 12.0 g/dL for adult women. For Black patients, additional tests, such as ferritin and transferrin saturation, are recommended to improve diagnostic accuracy. Update electronic health records and protocols by June 30 to comply with these standards. Training will be provided during the July staff meeting. Contact the Medical Board for guideline documents or support. (166 words)

Text 5: Public Health Notice

Subject: Mpox Vaccination Campaign Update

To: Community Health Workers

From: Public Health Ontario

Date: September 13, 2024

The MVA-BN vaccine, used during the 2022 outbreak, showed 58% effectiveness against laboratory-confirmed mpox infections in Ontario. It significantly reduced symptomatic cases and likely slowed transmission, aiding control. High-risk groups, particularly men who have sex with men, should be prioritized for the two-dose regimen. Health workers are responsible for promoting vaccination, educating communities on testing, and reinforcing prevention measures. Document vaccination status accurately and report uptake data by October 31. Sustained efforts are critical to maintaining low incidence. Contact Public Health Ontario for materials or support. (168 words)

Text 6: Oncology Department Bulletin

Subject: Updated Breast Cancer Irradiation Guidelines

To: Radiation Oncology Team

From: Dr. John Smith, Chief Oncologist

Date: June 7, 2025

The NSABP B-51 trial, involving 1641 breast cancer patients, found no benefit from regional nodal irradiation (RNI) in patients with node-positive disease achieving ypN0 status post-neoadjuvant chemotherapy. Recurrence-free survival was similar: 92.7% with RNI vs. 91.8% without (hazard ratio, 0.88; P=0.51). Omitting RNI reduces radiation exposure and side effects, like lymphedema. For ypN0 patients, focus on whole-breast irradiation after lumpectomy or no irradiation after mastectomy. Update treatment plans by June 15 and log changes in the oncology database. A mandatory briefing on June 10 will cover implementation and answer questions. This change enhances patient safety and aligns with international guidelines. Contact the department lead for the full trial report. (173 words)

Text 1: Omitting Regional Nodal Irradiation in Breast Cancer Patients Post-Neoadjuvant Chemotherapy

Authors: Eleftherios P. Mamounas, M.D., et al.

Published: June 4, 2025, N Engl J Med

Regional nodal irradiation (RNI) is a standard treatment for breast cancer patients with positive axillary lymph nodes, reducing locoregional recurrence. However, its necessity in patients achieving ypN0 status after neoadjuvant chemotherapy (NAC) is uncertain. NAC, typically involving anthracyclines, taxanes, or targeted therapies like trastuzumab, often downstages disease, allowing less invasive surgery and potentially eliminating RNI's benefit. The NSABP B-51 trial aimed to evaluate RNI's efficacy in this population, addressing concerns about overtreatment and radiation-related toxicities, such as lymphedema and dermatitis, which impact patient quality of life.

The trial enrolled 1641 patients with clinical stage T1–T3, N1, M0 breast cancer who achieved ypN0 status post-NAC. Participants were randomized to receive RNI (irradiation group, 50 Gy over 25 fractions) or no RNI (no-irradiation group). The primary endpoint was the invasive breast cancer recurrence–free interval (IBCRFI), defined as the time to local, regional, or distant recurrence or breast cancer-related death. Secondary endpoints included locoregional recurrence, distant recurrence, disease-free survival, and overall survival. Standardized radiation protocols and follow-up were maintained over a median of 59.5 months.

Results showed 109 IBCRFI events (50 in irradiation, 59 in no-irradiation). RNI did not improve IBCRFI (hazard ratio, 0.88; 95% CI, 0.60–1.28; P=0.51), with five-year rates of 92.7% (irradiation) vs. 91.8% (no-irradiation). Locoregional recurrence (3.2% vs. 3.5%), distant recurrence (5.0% vs. 5.4%), and overall survival (94.0% vs. 93.7%) were similar. These findings suggest RNI provides negligible benefit in ypN0 patients, challenging its routine use and supporting treatment de-escalation to reduce patient burden.

Adverse events were more frequent with RNI. Grade 3 toxicities, primarily radiation dermatitis and lymphedema, occurred in 4.5% of irradiated patients vs. 1.9% in the no-irradiation group. Grade 4 events, such as cardiac toxicity, were rare (0.5% vs. 0.1%). Arm swelling, affecting quality of life, was reported by 8.3% of irradiated patients. These safety data highlight the importance of minimizing radiation exposure when outcomes are comparable, reinforcing the case for omitting RNI in ypN0 patients.

Subgroup analyses explored tumor subtype effects. Hormone receptor–positive, HER2-negative patients showed a non-significant trend toward RNI benefit (hazard ratio, 0.80; 95% CI, 0.46–1.38), while triple-negative patients had a slightly higher recurrence risk with RNI (hazard ratio, 1.12; 95% CI, 0.65–1.93). Small subgroup sizes and wide confidence intervals limit these findings' applicability. Future studies should focus on subtype-specific outcomes to refine treatment protocols and identify patients who may still benefit from RNI.

The trial aligns with trends toward personalized breast cancer care. NAC's ability to eradicate nodal disease, combined with advances in systemic therapies (e.g., CDK4/6 inhibitors), likely reduces RNI's incremental benefit. The lower-than-expected event rate (109 vs. 200 anticipated) suggests improved prognosis, possibly due to enhanced systemic treatments or earlier detection. Omitting RNI in ypN0 patients minimizes toxicity while maintaining efficacy, streamlining clinical practice and improving patient well-being.

Limitations include lack of data on ypN0i+ patients (isolated tumor cells) and limited follow-up for late recurrences, particularly in hormone receptor–positive disease, which may occur after 5–10 years. Variability in radiotherapy techniques, such as intensity-modulated radiation therapy, may have introduced minor inconsistencies. Future research should incorporate genomic risk scores, longer follow-up, and standardized protocols to validate findings and explore RNI's role in high-risk subgroups.

The NSABP B-51 trial provides robust evidence for de-escalating treatment in ypN0 patients. Omitting RNI reduces radiation-associated toxicities without compromising outcomes, supporting patient-centered care. As systemic therapies evolve, RNI's relevance may further decline, emphasizing the need for ongoing trials to optimize adjuvant strategies. Clinicians should adopt these findings to enhance treatment decisions, balancing efficacy with minimal toxicity.

Text 2: A Trial of Trimethoprim–Sulfamethoxazole in Pregnancy to Improve Birth Outcomes

Authors: Bernard Chasekwa, M.Sc., et al.

Published: June 4, 2025, N Engl J Med

Maternal infections significantly contribute to adverse birth outcomes, particularly in high HIV-prevalence regions like sub-Saharan Africa. Trimethoprim–sulfamethoxazole (TMP-SMX), a broad-spectrum antibiotic with antimicrobial and immunomodulatory properties, is hypothesized to mitigate these risks by reducing inflammation-driven complications. The COMBI trial in Zimbabwe evaluated TMP-SMX prophylaxis during pregnancy to improve birth weight, a critical indicator of neonatal health. This study addresses a pressing need to enhance maternal care in low-resource settings, where adverse birth outcomes increase neonatal mortality and long-term health challenges.

The COMBI trial was a double-blind, randomized, placebo-controlled study involving 993 pregnant women aged 18–40 years in Harare and Bulawayo. Participants received TMP-SMX (960 mg daily) or placebo from ≥14 weeks' gestation (median 21.7 weeks) until delivery. Inclusion criteria included singleton pregnancies and no known TMP-SMX allergies. The primary outcome was mean birth weight (grams). Secondary outcomes included preterm birth (<37 weeks), low birth weight (<2500 g), small-for-gestational-age, and fetal loss. Adherence (>90%) was ensured through regular clinic visits and pill counts.

Results showed no significant difference in birth weight: 3040±460 g (TMP-SMX) vs. 3019±526 g (placebo); mean difference, 20 g (95% CI, −43 to 83; P=0.53). However, preterm births were significantly reduced in the TMP-SMX group (6.9% vs. 11.5%; relative risk, 0.60; 95% CI, 0.39–0.91; P=0.013). No differences were observed in low birth weight (10.2% vs. 10.0%), small-for-gestational-age (9.8% vs. 10.1%), or fetal loss (1.1% vs. 1.3%). These findings highlight TMP-SMX's selective benefit in preventing preterm births, a major cause of neonatal morbidity.

Safety data were reassuring, with adverse events comparable across groups. Mild gastrointestinal symptoms (nausea, vomiting) occurred in 10.3% of the TMP-SMX group vs. 9.7% of the placebo group. Serious adverse events, such as severe allergic reactions or hepatotoxicity, were rare (1.1% in both groups). Maternal HIV markers, including CD4 counts and viral load, remained stable, indicating TMP-SMX's effects were not mediated through HIV control. The trial's safety profile supports its potential use in pregnancy, pending further data on long-term neonatal outcomes.

Subgroup analyses showed a stronger preterm birth reduction among HIV-positive women (relative risk, 0.45; 95% CI, 0.23–0.88; P=0.019), likely due to TMP-SMX's prevention of opportunistic infections. Women with low CD4 counts (<200 cells/μL) showed similar trends, though not statistically significant. The lack of birth weight improvement may result from late intervention initiation (median 21.7 weeks), as early inflammation-driven damage may be irreversible. Zimbabwe's moderate HIV prevalence (~13%) may have diluted overall effects compared to higher-prevalence settings.

Strengths include the trial's rigorous design, high adherence, and diverse urban/rural recruitment. Limitations include limited post-delivery follow-up and lack of data on neonatal microbiome effects, which could influence long-term health outcomes. The trial has significant implications for maternity care in high HIV-prevalence regions. While universal TMP-SMX prophylaxis is not supported, its reduction in preterm births suggests benefits for high-risk groups, particularly HIV-positive women.

Clinicians should integrate these findings into patient counseling, emphasizing early prenatal care to maximize efficacy. Integration with HIV/AIDS programs could streamline implementation, leveraging antiretroviral infrastructure to improve maternal and neonatal outcomes. Future research should explore earlier TMP-SMX initiation (e.g., first trimester) to assess impacts on birth weight and other outcomes.

Long-term studies on neonatal development, including growth and neurocognitive outcomes, are needed to confirm safety. Trials in diverse settings with varying HIV and malaria prevalence could enhance generalizability. Combining TMP-SMX with nutritional interventions may address multiple adverse birth determinants, offering a holistic approach to maternal health.